JS203 in combination with gemcitabine and oxaliplatinJS203 in combination with ifosfamide, carboplatin and etoposideJS203 in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisoneJS203 combined with lenalidomide
JS203 in combination with gemcitabine and oxaliplatin: Gemcitabine and oxaliplatin 8 cycles (Q3W) and JS203 (21 days/cycle) Cycle 1 QW,Cycle 2 and therafter Q3W until progression or unacceptable toxicity.
JS203 in combination with ifosfamide, carboplatin and etoposide: Ifosfamide, carboplatin and etoposide, 3 cycles (Q3W) and JS203, Cycle 1 QW, Cycle 2 and therafter Q3W until trasnplant, progression or unacceptable toxicity.
JS203 in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone: Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone 6 cycles (Q3W) and JS203, 8 cycles (21 days/cycle), Cycle 1 QW, Cycle 2 to Cycle 8 Q3W.
JS203 combined with lenalidomide: lenalidomide,12 cycles, Cycle 1(Q3W), Cycle 2 to Cycle 12 (Q4W) and JS203, 12 cycles, Cycle 1 (21 days/cycle) QW, Cycle 2 to Cycle 12 (28 days/cycle) Q4W.
Study summary
To evaluate the preliminary efficacy of JS203 combined with standard regimens in patients with B-cell Non-Hodgkin's lymphoma
Eligibility
Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
Patients must meet all of the following inclusion criteria to be enrolled：
* Age range: 18 to 80 years old (inclusive), both male and female are acceptable；
* ECOG: 0-2；
* B-cell non-Hodgkin's lymphoma expressing CD20 antigen that has been pathologically diagnosed；
* At least one measurable lesion meeting the criteria specified in the Lugano 2014 response assessment； Acceptable organ function at screening；
Exclusion Criteria:
* A history of severe allergy to monoclonal antibody therapy (or recombinant antibody-related fusion protein)；
* Previously received CD20-CD3 bispecific antibody treatment；
* Previous allogeneic hematopoietic stem cell transplantation；
* Previous solid organ transplantation；
* History of autoimmune diseases；
* Patients with a history of macrophage activation syndrome (MAS)/ hemophagocytic lymphohistiocytosis (HLH)；
* Patients with a history of progressive multifocal leukoencephalopathy (PML)；
* A known or suspected history of CNS lymphoma (including primary or secondary)；
* There is pleural effusion, peritoneal effusion or pericardial effusion that requires treatment (such as puncture or drainage)；
Primary outcome measure(s)
Objective response rate (ORR) — up to approximately 15 months Objective response rate (ORR) based on 2014 Lugano criteria
Trial sites (1)
Facility
City
Region
Status
Beijing Cancer Hospital
Beijing
Beijing Municipality
More Shanghai Junshi Bioscience Co., Ltd. trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.